Stock Research: Glenmark Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Glenmark Pharmaceuticals

NSEI:GLENMARK INE935A01035
62
  • Value
    16
  • Growth
    93
  • Safety
    Safety
    51
  • Combined
    48
  • Sentiment
    82
  • 360° View
    360° View
    62
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. It operates in branded, generics, and OTC segments, focusing on Respiratory, Dermatology, Oncology, diabetes, cardiovascular, and oral contraceptives, with brands like RYALTRIS and SALMEX/ASTHMEX. The company develops products for markets such as India, Russia & CIS, Brazil, Asia, and Africa. In the last fiscal year, the company had a market cap of $7238 million, profits of $1050 million, and revenue of $1559 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 62 (better than 62% compared with alternatives), overall professional sentiment and financial characteristics for the stock Glenmark Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Glenmark Pharmaceuticals. The consolidated Value Rank has an attractive rank of 51, which means that the share price of Glenmark Pharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 51% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 93, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 82. But the company’s financing is risky with a Safety rank of 16. This means 84% of comparable companies have a safer financing structure than Glenmark Pharmaceuticals. ...read more

more
Index
Low Waste
Recycling
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
51 59 71 87
Growth
93 77 23 37
Safety
Safety
16 18 44 29
Sentiment
82 61 32 14
360° View
360° View
62 66 28 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
84 60 31 42
Opinions Change
43 50 38 35
Pro Holdings
n/a 25 21 26
Market Pulse
85 96 73 47
Sentiment
82 61 32 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
51 59 71 87
Growth
93 77 23 37
Safety Safety
16 18 44 29
Combined
48 54 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
61 64 75 89
Price vs. Earnings (P/E)
62 62 84 91
Price vs. Book (P/B)
51 59 81 87
Dividend Yield
29 18 23 40
Value
51 59 71 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
40 67 28 16
Profit Growth
71 98 26 53
Capital Growth
77 3 6 72
Stock Returns
89 95 95 33
Growth
93 77 23 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
28 46 26 18
Refinancing
39 28 76 84
Liquidity
25 14 38 24
Safety Safety
16 18 44 29

Similar Stocks

Discover high‑ranked alternatives to Glenmark Pharmaceuticals and broaden your portfolio horizons.

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

UPL

BSE:512070
Country: India
Industry: Fertilizers & Agricultural Chemicals
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.